Literature DB >> 12364637

Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia?

G Hein1, S Franke.   

Abstract

OBJECTIVE: To quantify the serum levels of the advanced glycation end-product (AGE) pentosidine in 41 patients with fibromyalgia (FM) and 46 healthy controls. The formation of pentosidine is closely related to oxidative stress.
METHODS: Pentosidine was measured by reverse-phased high-performance liquid chromatography with gradient separation on a RP-18 column.
RESULTS: Patients with FM have significantly higher pentosidine serum levels than healthy subjects.
CONCLUSION: AGE modification of proteins leads to reduced solubility and high resistance to proteolytic digestion of such altered proteins (e.g. AGE-modified collagens). AGEs are also able to stimulate different kinds of cells via activation of the NFkappaB, mediated by specific receptors of AGEs (e.g. RAGE) on the cell surface. Both mechanisms may contribute to the development, perpetuation and spreading of pain phenomena in FM patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364637     DOI: 10.1093/rheumatology/41.10.1163

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol; Ozge Ardicoglu; Hulya Yildizhan
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

2.  The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis.

Authors:  Gert E Hein; Markus Köhler; Peter Oelzner; Günter Stein; Sybille Franke
Journal:  Rheumatol Int       Date:  2004-12-03       Impact factor: 2.631

3.  Low plasma levels of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency-related fibromyalgia.

Authors:  Ignacio Blanco; Sabina Janciauskiene; Izabela Nita; Enrique Fernández-Bustillo; Victoriano Cárcaba; César Gallo; Marlene Alvarez-Rico; Frederick de Serres; Nana Béridze
Journal:  Clin Rheumatol       Date:  2009-11-19       Impact factor: 2.980

Review 4.  Bio-ecological control of chronic liver disease and encephalopathy.

Authors:  Stig Bengmark
Journal:  Metab Brain Dis       Date:  2008-12-23       Impact factor: 3.584

5.  Potential Mediators between Fibromyalgia and C-Reactive protein: Results from a Large U.S. Community Survey.

Authors:  Termeh Feinberg; Usha Sambamoorthi; Christa Lilly; Kim Karen Innes
Journal:  BMC Musculoskelet Disord       Date:  2017-07-07       Impact factor: 2.362

6.  Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease.

Authors:  Mario D Cordero; Manuel De Miguel; Ana M Moreno Fernández; Inés M Carmona López; Juan Garrido Maraver; David Cotán; Lourdes Gómez Izquierdo; Pablo Bonal; Francisco Campa; Pedro Bullon; Plácido Navas; José A Sánchez Alcázar
Journal:  Arthritis Res Ther       Date:  2010-01-28       Impact factor: 5.156

7.  Advanced glycation end-products and their receptor-mediated roles: inflammation and oxidative stress.

Authors:  Parisa Younessi; Ali Yoonessi
Journal:  Iran J Med Sci       Date:  2011-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.